SEC Form 4 · accession 0001213900-18-012382
Avant Diagnostics, Inc · AVDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael I Ruxin
Officer — Chief Executive Officer · Director
Period of report
Aug 23, 2018
Accepted (ET)
Sep 11, 2018 · 6:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001451929
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | — | Aug 23, 2018 | A | 25,000 | A | — | — | Common Stock | — | 25,000 | D |
Explanation of responses
- F1The Reporting Person purchased the Series A Preferred Stock from the Company on August 23, 2018. The Series A Preferred Stock has no expiration date and upon consummation of a reverse stock split of the Issuer's common stock such that after consummation of such reverse stock split there are approximately 15,000,000 shares of the Issuer's common stock outstanding, the holders shall take all necessary steps with the Issuer to exchange all outstanding shares of Series A Preferred Stock into shares of the Issuer's common stock at a rate to be agreed upon between the parties. The holders of Series A Preferred Stock collectively shall always constitute 50.1% of the voting power of the Issuer.